IFITM3 and acute myeloid leukemia: Specifically, in mice injected with Lv-shIFITM3-KG1a cells, the downregulation of IFITM3 expression led to a significant reduction in the expression levels of AML-associated immunological markers CD11b, CD33, and CD123.